Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
Adam Ioannou,1 Irene Tsappa,2 Sofia Metaxa,3 Constantinos G Missouris2,3 1Cardiology Department, Royal Free NHS Foundation Trust, London, UK; 2Cardiology Department, Medical School, University of Cyprus, Nicosia, Cyprus; 3Cardiology Department, Frimley Health NHS Foundation Trust, London, UK Abstrac...
Main Authors: | Ioannou A, Tsappa I, Metaxa S, Missouris CG |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-11-01
|
Series: | Patient Related Outcome Measures |
Subjects: | |
Online Access: | https://www.dovepress.com/non-valvular-atrial-fibrillation-impact-of-apixaban-on-patient-outcome-peer-reviewed-article-PROM |
Similar Items
-
Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation
by: Luca Masotti, et al.
Published: (2013-12-01) -
Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
by: Matthew A. Wanat, et al.
Published: (2019-10-01) -
CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01) -
Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
by: Chung-Ming Fu, et al.
Published: (2021-10-01) -
APIXABAN – FROM RECOMMENDATIONS TO EVERYDAY PRACTICE
by: L. N. ELISEEVA, et al.
Published: (2016-12-01)